All In Biotech

NDA 020186 · Teva Branded Pharm

Ziac

Bisoprolol Fumarate, Hydrochlorothiazide · Oral · Thiazide Diuretic

Last checked: Nov 19, 2026Latest source record: Jul 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1993

Mar 26, 1993

Approved uses

1

Original approval plus efficacy supplements

Registered trials

122

17 Phase 3, 16 recruiting

FAERS reports

620

443 serious, 54 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 11, 2026.

INDICATIONS AND USAGE Bisoprolol fumarate and hydrochlorothiazide tablets are indicated in the management of hypertension.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 26, 1993 Original approval · Type 4 - New Combination
3 products under this application
  • ZIAC · BISOPROLOL FUMARATE 2.5MG; HYDROCHLOROTHIAZIDE 6.25MG · TABLET, ORAL · Prescription · TE AB
  • ZIAC · BISOPROLOL FUMARATE 5MG; HYDROCHLOROTHIAZIDE 6.25MG · TABLET, ORAL · Prescription · TE AB
  • ZIAC · BISOPROLOL FUMARATE 10MG; HYDROCHLOROTHIAZIDE 6.25MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Bisoprolol" as an intervention, any sponsor and status, largest first.

All 122 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • headache50
  • fatigue44
  • drug ineffective43
  • nausea42
  • pruritus39
  • pain38
  • hypertension37
  • vomiting36
  • diarrhoea33
  • rash33
  • dyspnoea32
  • arthralgia31

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200422
200539
200618
200733
200841
200942
201075
201164
201295
20135
20147
201512
201620
201719
201824
201914
202012
202115
202215
20238
202414
202514
202612

Recalls

1 FDA enforcement reports for this application.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ziac (Bisoprolol/Hydrochlorothiazide)

2024 spending

$38K

Beneficiaries

18

37 claims

Per beneficiary

$2,119

$8.14 per unit

View as table
YearSpending
2020$163,421
2021$130,971
2022$132,871
2023$112,270
2024$38,147

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 499 on PubMed

Sponsor: Teva

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.